Increased concentrations of myeloperoxidase in serum and serum extracellular vesicles are associated with type 2 diabetes mellitus

•The MPO levels were elevated in serum EVs and serum in patients with T2DM.•The MPO levels in serum EVs and serum were independently associated with T2DM.•MPO may become potential inflammatory biomarker of T2DM. Inflammatory response plays a critical role in the initiation and progression of type 2...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinica chimica acta 2021-11, Vol.522, p.70-76
Hauptverfasser: Peng, Lu, Li, Xinwei, Li, Yu, Zhao, Wen, Nie, Shaoping, Yu, Huahui, Qi, Yue, Qin, Yanwen, Zhang, Huina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•The MPO levels were elevated in serum EVs and serum in patients with T2DM.•The MPO levels in serum EVs and serum were independently associated with T2DM.•MPO may become potential inflammatory biomarker of T2DM. Inflammatory response plays a critical role in the initiation and progression of type 2 diabetes mellitus (T2DM). Myeloperoxidase (MPO), a leukocyte-derived protagonist, exerts its proinflammatory properties in many complications. We explored the associations between serum extracellular vesicle (EV)-derived MPO as well as serum MPO and T2DM. We performed a cross-sectional study in 151 individuals, including 93 patients with T2DM and 58 non-T2DM controls. The concentrations of serum EV-derived MPO and serum MPO were measured by Luminex Assay. Our data showed that serum EV-derived MPO concentrations and serum MPO concentrations were significantly higher in T2DM patients compared with non-T2DM subjects. In addition, multivariate logistic regression analysis revealed that serum EV-derived MPO as well as serum MPO was independently associated with the presence of T2DM even after adjusting for confounding factors (OR = 1.836 /1 ng EV-derived MPO, 95% CI = 1.395–2.417, P 
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2021.08.010